Campone M - Search Results

1

Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.

Campone M, Juin P, André F, Bachelot T. Campone M, et al. Crit Rev Oncol Hematol. 2011 Jun;78(3):195-205. doi: 10.1016/j.critrevonc.2010.04.012. Epub 2010 Jun 1. Crit Rev Oncol Hematol. 2011. PMID: 20684884 Review.

2

[Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice].

Campone M, Fumoleau P. Campone M, et al. Bull Cancer. 2002 Mar;89(3):275-82. Bull Cancer. 2002. PMID: 11940467 Free article. Review. French.

3

[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application].

Campone M, Merlin JL, Fumoleau P. Campone M, et al. Bull Cancer. 2003 Jul;90(7):614-22. Bull Cancer. 2003. PMID: 12957803 Free article. Review. French.

4

[Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer].

Campone M, Kerbrat P, Roché H, Bennouna J, Cuillière JC, Le Mevel B, Fumoleau P. Campone M, et al. Bull Cancer. 2003 Oct;90(10):851-64. Bull Cancer. 2003. PMID: 14706914 Free article. Review. French.

5

[Cardiac dysfunction induced by trastuzumab].

Campone M, Bourbouloux E, Fumoleau P. Campone M, et al. Bull Cancer. 2004 Nov;91 Suppl 3:166-73. Bull Cancer. 2004. PMID: 15899624 Review. French.

6

Taxanes in adjuvant breast cancer setting: which standard in Europe?

Campone M, Fumoleau P, Bourbouloux E, Kerbrat P, Roché H. Campone M, et al. Crit Rev Oncol Hematol. 2005 Sep;55(3):167-75. doi: 10.1016/j.critrevonc.2005.04.003. Crit Rev Oncol Hematol. 2005. PMID: 16039867 Review.

7

Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis.

Tubiana-Hulin M, Spielmann M, Roux C, Campone M, Zelek L, Gligorov J, Samson J, Lesclous P, Laredo JD, Namer M. Tubiana-Hulin M, et al. Among authors: campone m. Crit Rev Oncol Hematol. 2009 Jul;71(1):12-21. doi: 10.1016/j.critrevonc.2008.10.009. Epub 2008 Dec 12. Crit Rev Oncol Hematol. 2009. PMID: 19070505 Review.

8

Lapatinib in metastatic breast cancer.

Frenel JS, Bourbouloux E, Berton-Rigaud D, Sadot-Lebouvier S, Zanetti A, Campone M. Frenel JS, et al. Among authors: campone m. Womens Health (Lond). 2009 Nov;5(6):603-12. doi: 10.2217/whe.09.54. Womens Health (Lond). 2009. PMID: 19863462 Free article. Review.

9

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA. Cortes J, et al. Among authors: campone m. J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467. Epub 2010 Aug 2. J Clin Oncol. 2010. PMID: 20679609 Clinical Trial.

10

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.

Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA. Andre F, et al. Among authors: campone m. J Clin Oncol. 2010 Dec 1;28(34):5110-5. doi: 10.1200/JCO.2009.27.8549. Epub 2010 Oct 25. J Clin Oncol. 2010. PMID: 20975068 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

401 results

Search Page

Filters